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We are not allowed to disclose such details as baseline findings and clinical outcomes including safety and efficacy endpoints for patients participating in the PREVAIL JAPAN and MDT-2111 clinical trials before their data are submitted. Thus, we retrospectively evaluated 15 patients with the Edwards SAPIEN prosthesis in the present study.
Methods

Subjects
We enrolled patients with severe aortic stenosis and cardiac symptoms for whom conventional surgery to replace the aortic valve was associated with high risk. Severe aortic stenosis was defined as aortic valve area <0.8 cm 2 or effective orifice area index <0.5 cm 2 /m 2 , mean aortic valve gradient ≥40 mmHg, or peak aortic jet velocity ≥4.0 m/s. All the patients had New York Heart Association class II or greater symptoms.
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At least 1 surgeon and 1 cardiologist had to agree that the patient was not a suitable candidate for surgery. Pertinent exclusion criteria were bicuspid or non-calcified aortic valve; diameter of aortic annulus based on trans-esophageal echocardiography <18 mm or >25 mm; aortic dissection or ilio-femoral dimensions or disease precluding safe sheath insertion; left ventricular ejection fraction (LVEF) <20%; untreated coronary artery disease requiring revascularization; severe (>3+) mitral or aortic regurgitation or prosthetic valve; acute myocardial infarction within previous 1 month; upper gastrointestinal bleeding within previous 3 months; transient ischemic attack or stroke within the previous 6 months; any cardiac procedure other than balloon valvuloplasty within previous 1 month or within previous 6 months for drug-eluting stent; and life expectancy <12 months due to associated non-cardiac comorbid condition.
Between October 2009 and February 2012, 124 patients with severe AS, who were considered to be inoperable or at high risk for conventional aortic valve surgery, were referred to Osaka University Graduate School of Medicine. We discussed therapies for these patients at the heart multi-disciplinary meetings attending by cardiac surgeons, cardiologists, and anesthesiologists. Consequently, in these high-risk patients, we performed TAVR in 51 patients, surgical AVR in 12 patients, and prescribed medication in 59 patients. The others (2 patients) had not undergone TAVR at the time of writing. Of the 51 TAVR patients, 15 underwent TAVR with SAPIEN, for which we are able to disclose the details. The patients were 9 men and 6 women, with a mean age of 83. Table 1 ). We evaluated clinical outcomes included 30-day mortality, hospital mortality, complications, and mid-term results. Statistical analysis was performed using JMP version 9 (SAS Institute). Data are given as mean ± SD. P<0.05 was considered statistically significant.
TAVR Procedure
Patients with adequate iliofemoral access underwent TAVR using an Edwards SAPIEN via a trans-iliofemoral approach with standard surgical cutdown of the common iliac artery or common femoral artery, and Retroflex III delivery system, while others underwent TAVR using an Edwards SAPIEN via a trans-apical approach with a mini left anterior thoracotomy and Ascendra delivery system. In particular, in patients with aortic disease including severe tortuosity of abdominal aorta, shaggy aorta except for ascending aorta, and aneurysms, we usually choose a trans-apical approach. In consequence, transapical approach and trans-iliofemoral were performed in 7 and 8 patients (femoral, 2; iliac, 6), respectively. All procedures were performed by a team composed of cardiac surgeons, cardiologists, and anesthesiologists in hybrid operating room. Under general anesthesia, balloon aortic valvuloplasty, and rapid ventricular pacing were routinely used. We used a 3-D navigation system with syngo DynaCT (Artis Zee; Siemens AG, Forchheim, Germany) to ensure precise deployment of devices in 8 cases. Furthermore, we routinely perform TAVR with cardiopulmonary support (CPS) in patients with low LV function (LVEF <40%) to avoid immediate conversion to on-pump technique due to hemodynamic instability. In consequence, we used elective CPS in 3 patients with low LV function. Transesophageal echocardiography was utilized during the procedure in all cases, except for 1 patient who had an intractable esophagus ulcer, in which case intracardiac echocardiography was utilized.
Results
Edwards SAPIEN valves were successfully implanted in all 15 patients without conversion to surgery. A 23-mm Edwards Data given as mean ± SD (range), or n (%). AVA, aortic valve area; LVEF, left ventricular ejection fraction; STS, Society of Thoracic Surgeons. Early Experiences of TAVR in Japan SAPIEN prosthesis was used in 10 patients and the 26-mm prosthesis was used in 5 patients ( Table 2) . Pre-implantation balloon valvuloplasty was done in all cases. In terms of perivalvular aortic regurgitation, none, trivial, and mild were found in 2 patients (13.3%), 1 patient (6.7%), and 12 patients (80%), respectively. Regarding intraoperative complications, an endovascular repair was required for dissection at the iliac approach site in 1 case. The mean operation time was 114±28 min (range, 75-180 min) and 12 patients (80%) were able to be extubated in the operating room. One patient who had the transapical approach required reoperation for bleeding on postoperative day 1. Furthermore, 1 patient with a huge abdominal aortic aneurysm and another with a descending aortic aneurysm underwent endovascular repair on postoperative day 1 and 51, respectively. There was no occurrence of perioperative stroke, while pacemakers were implanted in 2 patients (13.3%) for sick sinus syndrome and systolic anterior motion. At discharge, TTE demonstrated that there was significant hemodynamic improvement with a mean aortic valve area of 1.77±0.36 cm 2 (range, 1.22-2.43 cm 2 ) and mean pressure Data given as mean ± SD (range), or n (%). OR, operating room. Table 3 ). Duration of postoperative stay was 20.1± 12.0 days, and 11 patients achieved home discharge ( Table 4) . Except for 1 patient, all patients were alive with a mean follow-up period of 184 days (range, 11-848 days). One patient died of unknown cancer 7 months after operation. There was only 1 patient who had cardiovascular-related re-hospitalization ( Table 5 ). This patient underwent elective thoracic endovascular repair for a descending aortic aneurysm, which was found preoperatively.
Discussion
TAVR has recently been shown to be feasible for patients with severe AS who are considered inoperable, with satisfactory early results reported. 7- 9 We were the first to perform TAVR in Japan in October 2009. Presently, 2 clinical trials are underway and we have performed TAVR in 51 patients between October 2009 and February 2012. Early outcomes are satisfactory, although there have been some difficult cases, including poor calcification at the annulus, and low LV function. We have strategies for TAVR at Osaka University Graduate School of Medicine.
First, in patients with aortic disease, including severe tortuosity of abdominal aorta, shaggy aorta except for ascending aorta, and aneurysms, we usually choose a trans-apical approach. Discussion based on preoperative multislice computed tomography is mandatory to reduce the risk of serious complications such as aortic rupture or thromboembolisms. We note that such preoperative examinations were sufficiently thorough to prevent serious complications, and there were no strokes or hospital deaths in the present study.
Second, major complications may occur during the procedure and, in particular, patients with low LV function may require immediate conversion to an on-pump technique due to hemodynamic instability. Therefore, we routinely perform TAVR with CPS in patients with low LV function (LVEF <40%) and achieve acceptable outcomes. Because CPS time is usually short (approximately 10 min), we have seen no complications due to CPS.
Third, nearly all of the present patients were able to start early rehabilitation and the majority (n=12, 80%) were extubated in the operating room. We have tried to reduce postoperative pain especially in the case of trans-apical approach. In consequence, 9 continuous patients, including 4 patients who had the trans-apical approach, achieved extubation in the operating room. Because TAVR is less invasive than conventional AVR, patients can achieve early extubation and start early rehabilitation, thereby reducing the rate of perioperative complications. Consequently, we achieved short postoperative stay (20.1±12.0 days) and a relatively high rate of home discharge (73.3%) even in high-surgical-risk patients. Data given as n (%). DTA, descending thoracic aorta; TEVAR, thoracic endovascular aortic repair.
